Summaries from SSAC projects approved year 2023
SLS-986613
The aim was to estimate the cumulative incidence, risk factors, and prognosis of post-transplant lymphoproliferative disorder (PTLD) of PTLD in EBV-seronegative patients undergoing kidney transplantation at Odense, Aarhus, and Oslo University Hospital in 2007-2021. Eighty of 5,084 kidney transplant recipients were diagnosed with PTLD. In total, 7.3% of EBV-seronegative adults and 14.1% of EBV-seronegative children developed PTLD within 2 years post-transplant. Induction therapy with anti-thymocyte globulin (ATG) was associated with an increased risk of PTLD, HR=4.4 (95% CI 1.8-10.6), while rituximab was associated with a lower risk, HR=0.20 (95% 0.03-1.49) post-transplant. The five-year cumulative mortality in adults diagnosed with PTLD was 46.2%. In conclusion, induction therapy with ATG should be avoided in EBV-seronegative kidney transplant recipients. Although rituximab may lower the risk of PTLD, it remains unclear whether its infection-related adverse effects outweigh this benefit.
SLS-986331
The study is currently still including participants in Guinea-Bissau and Ethiopia. End of inclusion is september 2025. We have so far included 566 participants in Bissau and 1267 in Gondar. In April 2025 the last two clusters in Bissau and Gondar were switched to intervention, so the intervention is now running at all 4 clusters.
SLS-987114
Antimicrobial resistance is a serious threat to the effectiveness of our clinical antibiotics. Therefore, new strategies are required in drug development to address this. The project focuses on the destroying essential proteins in bacteria, rather then inhibiting their action. To do this, we have designed bifunctional degraders with the goal of recruiting a protein of interest to the bacterial proteasome for degradation. Initial proof of concept has been shown for this strategy and further development is ongoing.
SLS-986553
Thank you NSCMID for giving us the opportunity to examine the associations between infections and type 2 diabetes. We intend to keep doing research on primary healthcare infections and antimicrobial chemotherapy!
SLS-986462
Mecillinam as a standalone agent showed efficacy against most NDM and KPC producers (except IMP). Avibactam combinations restored susceptibility in mecillinam-resistant K. pneumoniae isolates (KPC+OXA-48, KPC-2). Ceftibuten/avibactam was ineffective against metallo-β-lactamase (NDM, VIM) producers, consistent with avibactam’s lack of activity against class B enzymes. As such, mecillinam (± avibactam) could be a viable option for NDM/KPC-producing Enterobacterales, particularly in E. coli and K. pneumoniae. Ceftibuten/avibactam may address ESBL, KPC, or OXA-48-like infections but not MBL producers. IMP producers exhibited cross-resistance, warranting alternative strategies. Cefepime/enmetazobactam showed limited activity, primarily effective against isolates lacking MBLs; the exceptions were the VIM-4 producing isolate being susceptible.
More information,
Kind regards,
Karina Umander
RESEARCH ADMINISTRATOR
070 695 60 95
karina.umander@sls.se
